Open AccessLong-lasting response with lapatinib treatment: a case report
Author(s) -
Andrea Milani,
Imperia Nuzzolese,
Giovanna Chilà
Publication year - 2018
Publication title -
aboutopen
Language(s) - English
Resource type - Journals
ISSN - 2465-2628
DOI - 10.19156/abtpn.2018.0030
Subject(s) - lapatinib , capecitabine , medicine , oncology , central nervous system , metastatic breast cancer , disease , cancer , breast cancer , lesion , trastuzumab , pathology , colorectal cancer
Lapatinib is a small molecule and a reversible inhibitor of HER2, which has shown to be effective on brain lesions in patients with HER2-positive breast cancer relapsed at the central nervous system (CNS). We report the clinical case of a young woman, treated with the combination of lapatinib and capecitabine from September 2009 to today for a metastatic recurrence of HER2-positive breast carcinoma at CNS level and who has achieved a complete response of the encephalic lesion and has not shown disease progression at systemic or CNS level, with excellent tolerance profile (Oncology).